Related Experiment Video
Updated: May 27, 2026

Chronic Post-Ischemia Pain Model for Complex Regional Pain Syndrome Type-I in Rats
Published on: January 21, 2020
MicroRNA modulation in complex regional pain syndrome
Irina A Orlova1, Guillermo M Alexander, Rehman A Qureshi
1Pharmacology & Physiology, Drexel University College of Medicine, Philadelphia, PA 19102, USA.
Background:
Aberrant expression of small noncoding RNAs called microRNAs (miRNAs) is a common feature of several human diseases. The objective of the study was to identify miRNA modulation in patients with complex regional pain syndrome (CRPS) a chronic pain condition resulting from dysfunction in the central and/or peripheral nervous systems. Due to a multitude of inciting pathologies, symptoms and treatment conditions, the CRPS patient population is very heterogeneous. Our goal was to identify differentially expressed miRNAs in blood and explore their utility in patient stratification.
Methods:
We profiled miRNAs in whole blood from 41 patients with CRPS and 20 controls using TaqMan low density array cards. Since neurogenic inflammation is known to play a significant role in CRPS we measured inflammatory markers including chemokines, cytokines, and their soluble receptors in blood from the same individuals. Correlation analyses were performed for miRNAs, inflammatory markers and other parameters including disease symptoms, medication, and comorbid conditions.
Results:
Three different groups emerged from miRNA profiling. One group was comprised of 60% of CRPS patients and contained no control subjects. miRNA profiles from the remaining patients were interspersed among control samples in the other two groups. We identified differential expression of 18 miRNAs in CRPS patients. Analysis of inflammatory markers showed that vascular endothelial growth factor (VEGF), interleukin1 receptor antagonist (IL1Ra) and monocyte chemotactic protein-1 (MCP1) were significantly elevated in CRPS patients. VEGF and IL1Ra showed significant correlation with the patients reported pain levels. Analysis of the patients who were clustered according to their miRNA profile revealed correlations that were not significant in the total patient population. Correlation analysis of miRNAs detected in blood with additional parameters identified miRNAs associated with comorbidities such as headache, thyroid disorder and use of narcotics and antiepileptic drugs.
Conclusions:
miRNA profiles can be useful in patient stratification and have utility as potential biomarkers for pain. Differentially expressed miRNAs can provide molecular insights into gene regulation and could lead to new therapeutic intervention strategies for CRPS.
Insights
MicroRNA (miRNA) profiles in blood can help stratify patients with complex regional pain syndrome (CRPS). These differentially expressed miRNAs may serve as biomarkers for pain and offer new therapeutic targets for CRPS.
Area of Science:
- Biochemistry
- Genetics
- Immunology
Background:
- Aberrant microRNA (miRNA) expression is implicated in various human diseases.
- Complex Regional Pain Syndrome (CRPS) is a heterogeneous chronic pain condition with central and/or peripheral nervous system dysfunction.
- Identifying specific miRNA modulations in CRPS patients is crucial for understanding disease mechanisms.
Purpose of the Study:
- To identify differentially expressed miRNAs in the blood of CRPS patients.
- To explore the utility of these miRNAs in stratifying CRPS patients.
- To investigate the relationship between miRNA profiles, inflammatory markers, and clinical parameters in CRPS.
Main Methods:
- miRNA profiling was performed on whole blood samples from 41 CRPS patients and 20 controls using TaqMan low density array cards.
- Inflammatory markers (chemokines, cytokines, soluble receptors) were measured to assess neurogenic inflammation.
- Correlation analyses were conducted between miRNA expression, inflammatory markers, disease symptoms, medication, and comorbidities.
Main Results:
- Three distinct miRNA profile groups were identified, with one group containing 60% of CRPS patients and no controls.
- Eighteen miRNAs were found to be differentially expressed in CRPS patients.
- Elevated levels of vascular endothelial growth factor (VEGF), interleukin-1 receptor antagonist (IL1Ra), and monocyte chemotactic protein-1 (MCP1) were observed in CRPS patients, with VEGF and IL1Ra correlating with pain levels.
Conclusions:
- miRNA profiles demonstrate potential for CRPS patient stratification and serve as biomarkers for pain.
- Differentially expressed miRNAs offer molecular insights into gene regulation relevant to CRPS.
- These findings could pave the way for novel therapeutic strategies targeting miRNA pathways in CRPS.
Related Concept Videos
Analgesia and Pain Management
MicroRNAs
MicroRNAs
